Zhitong Financial APP News, Yingjian Medical (01419) announced its annual results for the year ended June 30, 2023, with revenue of about HK $1.002 billion, a decrease of about 10.7% compared with the same period last year. Gross profit was about HK $593 million, down about 10.1 per cent from a year earlier. The profit attributable to the owners of the company was about HK $181 million, down about 51.8 per cent from a year earlier. Basic earnings per share is approximately HK47.6 cents, with a final dividend of HK16 cents per share.
The decrease in revenue was mainly due to reduced demand for 2019 coronavirus disease-related prevention, testing, vaccination and outreach services, the announcement said.
The decrease in profit was mainly due to a decrease in revenue from general practice services due to a decrease in demand for epidemic-related prevention, testing, vaccination and outreaching services, and a decrease in gross profit due to a decrease in revenue from general practice services; the Group's net fair value change in financial assets and investment properties in fair value included in profit or loss changed from fair value net income in fiscal year 2022 to fair value net loss in fiscal year 2023; and increased impairment of property, plant and equipment.
In addition, on September 26, 2023, the board of directors decided to recommend the adoption of the share incentive scheme for shareholders' approval.